Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Comparison of efficacy of pregabalin with duloxetine in the management of patients with painful diabetic neuropathy.

View through CrossRef
Objectives: To compare pregabalin with duloxetine in terms of mean reduction in pain score, in the management of patients with painful diabetic neuropathy. Study Design: Randomized Controlled Trial. Setting: Department of Medicine, FMU & Affiliated Hospitals, Faisalabad. Period: 1st March, 2020 to 3rd March 2021. Material & Methods: A total of 180 patients with known diabetics of at least 5 years duration, 18 to 75 years of age were included. Patients with ischemic pain or other types of pain not related to diabetes such as arthritic pain or phantom pain secondary to amputations, CRF & CLD were excluded. Group A received 150mg of Pregabalin at night before sleeping and was increased to 150mg twice daily after 02 week if VAS pain score reduction was found to be less than 50% from baseline. Group B received 60mg Duloxetine at bed time and it was increased to 120mg after 04 weeks if the VAS pain score was less than 50% after 04 weeks. The patients were again assessed after another 04 weeks to assess VAS Pain Score reduction. The primary outcome is pain as assessed by the Visual Analogue Score (VAS) at the end of 04 weeks from start of medications. Results: Age range in this study was from18 to75 years with mean age of 40.87±13.67 years. The mean age of patients in pregabalin group was 38.80 ± 13.01 years and in duloxetine group was 41.07 ± 13.85 years. Majority of the patients 34 (56.67%) were between 20 to 40 years of age. Mean reduction in pain in pregabalin group was 1.63 ± 1.07 while in duloxetine group was 3.23 ± 1.38 (p-value =0.0001). Conclusion: This study concluded that duloxetine had significantly greater pain reduction than pregabalin in the management of patients with painful diabetic neuropathy.
Title: Comparison of efficacy of pregabalin with duloxetine in the management of patients with painful diabetic neuropathy.
Description:
Objectives: To compare pregabalin with duloxetine in terms of mean reduction in pain score, in the management of patients with painful diabetic neuropathy.
Study Design: Randomized Controlled Trial.
Setting: Department of Medicine, FMU & Affiliated Hospitals, Faisalabad.
Period: 1st March, 2020 to 3rd March 2021.
Material & Methods: A total of 180 patients with known diabetics of at least 5 years duration, 18 to 75 years of age were included.
Patients with ischemic pain or other types of pain not related to diabetes such as arthritic pain or phantom pain secondary to amputations, CRF & CLD were excluded.
Group A received 150mg of Pregabalin at night before sleeping and was increased to 150mg twice daily after 02 week if VAS pain score reduction was found to be less than 50% from baseline.
Group B received 60mg Duloxetine at bed time and it was increased to 120mg after 04 weeks if the VAS pain score was less than 50% after 04 weeks.
The patients were again assessed after another 04 weeks to assess VAS Pain Score reduction.
The primary outcome is pain as assessed by the Visual Analogue Score (VAS) at the end of 04 weeks from start of medications.
Results: Age range in this study was from18 to75 years with mean age of 40.
87±13.
67 years.
The mean age of patients in pregabalin group was 38.
80 ± 13.
01 years and in duloxetine group was 41.
07 ± 13.
85 years.
Majority of the patients 34 (56.
67%) were between 20 to 40 years of age.
Mean reduction in pain in pregabalin group was 1.
63 ± 1.
07 while in duloxetine group was 3.
23 ± 1.
38 (p-value =0.
0001).
Conclusion: This study concluded that duloxetine had significantly greater pain reduction than pregabalin in the management of patients with painful diabetic neuropathy.

Related Results

A Study on the Effects of Pregabalin and Amitriptyline in Treatment of Patients with Painful Diabetic Neuropathy
A Study on the Effects of Pregabalin and Amitriptyline in Treatment of Patients with Painful Diabetic Neuropathy
Objective: To compare the effect of Amitriptyline and Pregabalin in treatment of painful diabetic neuropathy. Material and Methods: The design of this study was Randomized Controll...
Impact of Diabetic Neuropathy on Ankle Dorsiflexion in Older Adults
Impact of Diabetic Neuropathy on Ankle Dorsiflexion in Older Adults
Background: Diabetes mellitus is increasing among the population. If early diagnosis and treatment can be done, complications can be reduced. Although there are studies evaluating ...
Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder
Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder
Background/Objectives: This study aimed to investigate plasma duloxetine concentrations, factors influencing these concentrations, and the relationship between plasma levels and cl...
QbD-Optimized RP-HPLC Method Development for Simultaneous Quantification of Pregabalin and Duloxetine Hydrochloride
QbD-Optimized RP-HPLC Method Development for Simultaneous Quantification of Pregabalin and Duloxetine Hydrochloride
Quality by design (QbD) is a systematic approach focused on achieving consistent, predictable quality based on predefined objectives. Unlike traditional methods, QbD prioritizes ri...
Survival, incidence, and predictors of diabetic neuropathy among type 2 diabetic patients in hospitals of Addis Ababa
Survival, incidence, and predictors of diabetic neuropathy among type 2 diabetic patients in hospitals of Addis Ababa
BackgroundDiabetic neuropathy is a very common complication of diabetes mellitus. Thus, measuring the incidence of diabetic neuropathy is a key element in tracking the progress of ...
Pregabalin in fibromyalgia - responder analysis from individual patient data
Pregabalin in fibromyalgia - responder analysis from individual patient data
Abstract Background Population mean changes are difficult to use in clinical practice. Responder analysis may be better, but needs validating for...

Back to Top